Seeking Alpha

TAHO Pharmaceuticals Reports Positive Results from Pivotal Study of TAH3311, the First Oral Dissolving Film Anticoagulant

TAIPEI, Feb. 17, 2025 /PRNewswire/ -- TAHO Pharmaceuticals announces positive preliminary results from the pivotal study of TAH3311, the world's first Apixaban oral dissolving film (ODF). The study ...

The beginning of the end: Eliquis sales forecast to plummet as EU patent expiry nears

The BMS-Pfizer alliance has dominated the anticoagulant drug market, earning approximately $82.6bn in revenue since 2011.
The Cardiology Advisor

Apixaban Linked to Higher Gastrointestinal Bleed Risk Than Aspirin in SCAF

While apixaban was linked to more total major bleeds, rates of fatal and intracranial hemorrhage were similar to aspirin.
Morningstar

TAHO Pharma Announces Submission of New Drug Application (NDA) to the U.S. FDA for TAH3311 - The World's First Apixaban Oral Dissolving Film - Represents a Transformational ...

TAIPEI, Oct. 1, 2025 /PRNewswire/ -- TAHO Pharmaceuticals Ltd. ("TAHO Pharma") today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ...